Harmony Biosciences (HRMY) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
3 Apr, 2026Executive summary
Annual meeting scheduled for May 14, 2026, to be held virtually for shareholder participation.
Shareholders are encouraged to review proxy materials and vote by May 13, 2026.
Voting matters and shareholder proposals
Election of four Class III directors to serve until the 2029 annual meeting, with nominees Geno J. Germano, Troy Ignelzi, Ron Philip, and Andreas Wicki, Ph.D.
Ratification of Deloitte & Touche LLP as independent registered public accounting firm for fiscal year ending December 31, 2026.
Advisory vote on executive compensation in accordance with SEC disclosure rules.
Provision for other business to be transacted as may properly come before the meeting.
Board of directors and corporate governance
Board recommends voting in favor of all director nominees and proposals.
Latest events from Harmony Biosciences
- Pipeline advances and new formulations target CNS and epilepsy markets, driven by strong sales.HRMY
Piper Sandler Virtual CNS Symposium - Q2 2026 revenue up 30% to $261.3M, with strong WAKIX growth and pipeline advancement.HRMY
Q2 2026 - Four-pillar strategy drives WAKIX growth, orexin pipeline, and targeted business development.HRMY
Goldman Sachs 47th Annual Global Healthcare Conference 2026 - Directors were elected, auditor ratified, and executive pay approved, with Q&A held.HRMY
AGM 2026 - Q1 2026 revenue up 17% to $215.4M; full-year guidance reaffirmed at $1.0–$1.04B.HRMY
Q1 2026 - WAKIX momentum, pipeline innovation, and strategic BD drive growth and CNS leadership.HRMY
25th Annual Needham Virtual Healthcare Conference - 2025 revenue up 22% year-over-year; 2026 WAKIX guidance set at $1.0–$1.04B.HRMY
Q4 2025 - Q1 2025 revenue up 20% to $184.7M, net income $45.6M, and 2025 guidance reaffirmed.HRMY
Q1 2025 - 2024 revenue up 23% to $714.7M, with strong WAKIX sales and robust 2025 growth outlook.HRMY
Q4 2024